Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]
Radioligand therapy transformed advanced prostate cancer care with PSMA targeting. Now experts eye options for PSMA-resistant or low-expression cases. At APCCC 2026, Dr. Ken Herrmann named ACP3, B7-H3, and STEAP1/STEAP2 as top priorities. These could reach patients (outside clinical trials) in four to five years. ACP3, or prostatic acid phosphatase, binds tighter than PSMA in […]
Xaluritamig (AMG 509) represents a promising new immunotherapy option for men with metastatic castration-resistant prostate cancer, or mCRPC, through this new Phase 1 trial. The study aims to evaluate the safety profile of xaluritamig administered as monotherapy (plus ADT, as usual) at a specific proposed regimen in adult male participants whose cancer has progressed despite […]
QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]
HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]
STEAP1 is a protein that sits on the surface of many prostate cancer cells, especially in advanced metastatic disease. Because it is abundant on cancer cells and much less present in normal tissues, STEAP1 looks like a promising “flag” that engineered immune cells can use to distinguish tumor from healthy organs. The treatment being […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy